MGTX - MeiraGTx Holdings plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

MeiraGTx Holdings plc

430 East 29th Street
10th Floor
New York, NY 10016
United States
646-490-2965
http://www.meiragtx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees130

Key Executives

NameTitlePayExercisedYear Born
Dr. Alexandria ForbesCEO, Pres & Director10.27MN/A1965
Mr. Richard Brian GirouxCOO & CFO9.58MN/A1973
Dr. Stuart Naylor Ph.D.Chief Devel. Officer1.14MN/A1963
Ms. Elizabeth BroderVP of Investor RelationsN/AN/AN/A
Mr. Micah ZajicVP of Corp. Devel.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was founded in 2015 and is headquartered in New York, New York.

Corporate Governance

MeiraGTx Holdings plc’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.